Imbiologics

Developer of antibody therapeutics to treat cancer and autoimmune diseases

placeSuwon-si, Gyeonggi-do, South Korea calendar_todayFounded 2020 groups25 employees language imbiologics.com

Innovation

7 patent families (2 granted) — focus: Chemistry & metallurgy, Physics & computing; filing pace accelerating. Cited 98 times.

YearFilings
20223
20233
20243
20255
20261

Investor mix

18 investors on record; lead investors include KB Investment, Atinum Investment, Partners Investment, CJ Investment.

Investor typeCountShare
Venture capital844%
Private equity317%
Bank & private debt211%
Other / undisclosed528%
Coming soon